A question that surfaces repeatedly in extracellular vesicle (EV) method development is whether two desirable properties can be held at the same time: a complete, unbiased EV population isolated without affinity capture, and a preparation that carries no risk of contaminating virus.
Diafiltration, the process of adding fresh buffer to a sample while simultaneously removing permeate, extends the tangential flow filtration technique into a far more powerful tool
The combination of Tangential Flow Filtration (TFF) and size exclusion chromatography (SEC) is a widely used workflow for the isolation of virus-like proteins (VLPs).
A systematic look at how to optimize TFF for EV purification: what each parameter controls, how to set it, and how to confirm that the resulting preparation meets the quality standards that downstream work, whether cargo analysis, functional assay or therapeutic manufacture, demands.
Three analytical layers dominate EV analysis. Proteomics catalogues the proteins, transcriptomics profiles the RNA, and lipidomics maps the membrane lipids. Together they form the core of EV cargo analysis.
How neuron-derived extracellular vesicles (NDEVs) carry amyloid-beta, tau and alpha-synuclein between neurons and provide blood biomarkers for Alzheimer's, Parkinson's, ALS and FTD, plus the growth factor and EV isolation tools that support the work.
Three single-particle methods dominate the modern EV characterisation toolkit: nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (TRPS) and microfluidic resistive pulse sensing (MRPS). Which should you choose? Or do you need them all?
Several methods have emerged that dominate the field of extracellular vesicle (EV) isolation. Beyond these, many interesting alternatives are on the horizon.
Not all extracellular vesicles are the same. Learn how exosomes, microvesicles and apoptotic bodies differ in size, biogenesis and cargo, and why the distinction matters for reproducible EV research.
MSC-derived exosomes (and other extracellular vesicles) have become one of the most actively investigated modalities in regenerative medicine, with peer-reviewed evidence spanning cardiac repair, neural regeneration, wound healing, bone and cartilage restoration, and acute organ injury. This article reviews the biological basis of MSC exosome activity, the therapeutic evidence across key disease areas, the manufacturing and isolation considerations that determine product quality, and the tools available to researchers establishing MSC exosome programmes.
